Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I bioequivalence study of oral and intravenous topiramate

Trial Profile

Phase I bioequivalence study of oral and intravenous topiramate

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topiramate (Primary) ; Topiramate (Primary)
  • Indications Epilepsy; Migraine; Neonatal seizures
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Apr 2015 Results of a pooled analysis of the negative effects of topiramate on verbal fluency in the IV/IR study (profile 700234568) and the SPN-538/IR study (profile 210651) were presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 04 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top